Open Access

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Topic: Heart Failure
Sponsored by Charité Berlin - Supported by an unrestricted educational grant from The Boehringer Ingelheim and Lilly Alliance

Presentation

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)
53 presentations
1 follower

5 more presentations in this session

Introduction: SGLT2 inhibitors beyond glycemic control.

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Thumbnail

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Speaker: Doctor M. Packer (Dallas, US)

Thumbnail

Renal benefits of SGLT2 inhibitors in HF patients.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Effects of SGLT2 inhibitors on quality of life in HF.

Speaker: Professor J. Butler (Jackson, US)

Thumbnail

Conclusion.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Access the full session

SGLT2 inhibition in heart failure: what have we learned so far?

Speakers: Professor G. Filippatos, Doctor S. Zieroth, Doctor M. Packer, Professor F. Zannad, Professor J. Butler...
Thumbnail

About the event

Image

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Related content

ESC Premium Access

Universal definition of heart failure and new classifications.

29 August 2021

Open Access

EMPEROR-Reduced and EMPEROR-Preserved: patient-level pooled analysis.

29 August 2021

ESC Premium Access

High-sensitivity cardiac troponin in DAPA-HF

27 August 2021

This platform is supported by

logo Novo Nordisk